Thymalfasin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Discovered by Tillett and Francis in 1930, it was initially thought that CRP might be a pathogenic secretion since it was elevated in a variety of illnesses, including cancer. The later discovery of hepatic synthesis (made in the liver) demonstrated that it is a native protein. Initially, CRP was measured using the quellung reaction which gave a positive or a negative result. More precise methods nowadays use dynamic light scattering after reaction with CRP-specific antibodies. CRP was so named because it was first identified as a substance in the serum of patients with acute inflammation that reacted with the cell wall polysaccharide (C-polysaccharide) of pneumococcus.
=== Coordination complexes === There is much interest in the coordination chemistry of neptunium, because its five oxidation states all exhibit their own distinctive chemical behavior, and the coordination chemistry of the actinides is heavily influenced by the actinide contraction (the greater-than-expected decrease in ionic radii across the actinide series, analogous to the lanthanide contraction).
Insulin resistance is decreased Adipocyte differentiation is modified VEGF-induced angiogenesis is inhibited Leptin levels decrease (leading to an increased appetite) Levels of certain interleukins (e.g. IL-6) fall Antiproliferative action Adiponectin levels rise TZDs also increase the synthesis of certain proteins involved in fat and glucose metabolism, which reduces levels of certain types of lipids, and circulating free fatty acids. TZDs generally decrease triglycerides and increase high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). Although the increase in LDL-C may be more focused on the larger LDL particles, which may be less atherogenic, the clinical significance of this is currently unknown. Nonetheless, rosiglitazone, a certain glitazone, was suspended from allowed use by medical authorities in Europe, as it has been linked to an increased risk of heart attack and stroke.
Sources: en.wikipedia.org
== Discovery == p53 was identified in 1979 by Lionel Crawford, David P. Lane, Arnold Levine, and Lloyd Old, working at Imperial Cancer Research Fund (UK), Princeton University/UMDNJ (Cancer Institute of New Jersey), and Memorial Sloan Kettering Cancer Center, respectively. It had been hypothesized to exist before as the target of the SV40 virus, a strain that induced development of tumors. The name p53 is in fact a misnomer, as it describes the apparent molecular mass measured when it was first discovered, though it was later realised this was an overestimate: the correct molecular mass is only 43.7 kDa. The TP53 gene from the mouse was first cloned by Peter Chumakov of the Academy of Sciences of the USSR in 1982, and independently in 1983 by Moshe Oren in collaboration with David Givol (Weizmann Institute of Science). The human TP53 gene was cloned in 1984 and the full length clone in 1985. It was initially presumed to be an oncogene due to the use of mutated cDNA following purification of tumor cell mRNA. Its role as a tumor suppressor gene was revealed in 1989 by Bert Vogelstein at the Johns Hopkins School of Medicine and Arnold Levine at Princeton University. p53 went on to be identified as a transcription factor by Guillermina Lozano working at MD Anderson Cancer Center. Warren Maltzman, of the Waksman Institute of Rutgers University first demonstrated that TP53 was responsive to DNA damage in the form of ultraviolet radiation.
Despite his triumph in Rome, he lost his opening round match at the French Open. During the grass court season, Zverev made another singles final and again faced Federer at the Halle Open, but could not defeat him this time. He and his brother also finished runner-up in the doubles event to Łukasz Kubot and Marcelo Melo. At Wimbledon, he achieved his best result at a major event to date, ultimately losing in the fourth round to the previous year's runner-up Milos Raonic in a tight five-set match. Back on hard courts, Zverev won his last two titles of the season in August. He won the Washington Open as well as a second consecutive Masters title at the Canadian Open, only dropping a single set at each tournament in each of his opening matches. Notably, he needed to save three match points in his first match in Canada against Richard Gasquet, including a 49 shot rally. He then defeated Roger Federer in the final to become the first player outside of the Big Four to win multiple Masters titles in the same season since David Nalbandian in 2007. Despite this success, he was upset in the second round of the US Open by fellow Next Gen player Borna Ćorić. At the end of the season, Zverev qualified for both the inaugural Next Generation Finals as one of the top seven 21-and-under players, and the ATP Finals as one of the top eight players in the world. He opted to skip the former event to focus on the latter. At the ATP Finals, Zverev was grouped with Roger Federer, Marin Čilić, and Jack Sock.
In 1840, the Cossack hosts included the Don, Black Sea, Astrakhan, Little Russia, Azov, Danube, Ural, Stavropol, Mesherya, Orenburg, Siberian, Tobolsk, Tomsk, Yeniseisk, Irkutsk, Sabaikal, Yakutsk, and Tartar voiskos. In the 1890s, the Ussuri, Semirechensk, and Amur Cossacks were added; the last had a regiment of elite mounted rifles. Increasingly as the 19th century went on, the Cossacks served as a mounted para-military police force in all of the various provinces of the vast Russian Empire, covering a territory stretching across Eurasia from what is now modern Poland to the banks of the river Amur that formed the Russian-Chinese border. The police forces of the Russian Empire, especially in rural areas, were undermanned owing to the low wages while the officers of the Imperial Russian Army disliked having their units deployed to put down domestic unrest, which was viewed as destructive of morale and possibly an incentive to mutiny. For the government, deploying Cossacks as a para-military police force was the best solution as the Cossacks were viewed as one of the social groups most loyal to the House of Romanov while their isolation from local populations was felt to make them immune to revolutionary appeals. Traditionally, Cossacks were viewed in Russia as dashing, romantic horsemen with a rebellious and wild aura about them, but their deployment in the role of a mounted police force gave them a "novel" image as a rather violent and thuggish institution fiercely committed to upholding the social order.
== Eukaryotic analogue == The complexity in bacterial responses appears to be in the number of proteins induced by oxidative stress. In mammalian cells, the number of proteins induced is small but the regulatory pathways are highly complex. The inducers of oxidative stress responses in bacteria appear to be either the oxidant itself or interaction of the oxidant with a cell component. Most mammalian cells exist in an environment where the oxygen concentration is constant, thus responses are not directly stimulated by oxidants. Rather, cytokines such as tumor necrosis factor, interleukin-1 or bacterial polysaccharides induce SOD synthesis and multigene responses. Recent work shows that superoxide is a strong tumor promoter that works by activation and induction growth-competence related gene products. Other factors involved in the antioxidant gene expression include an induction of calmodulin kinase by increase in Ca2+ concentrations. E. coli cells have revealed similarities to the aging process of higher organisms. The similarities include increased oxidation of cellular constituents and its target specificity, the role of antioxidants and oxygen tension in determining life span, and an apparent trade-off between activities related to reproduction and survival.
Sources: en.wikipedia.org
== Development and social impact == John Rolfe of Virginia used this species of tobacco to break the Spanish monopoly on tobacco in 1612. He did so by obtaining Nicotiana tabacum - the coveted plant he had designs to replace Nicotiana rustica with. Up until 1612, Nicotiana rustica was Virginia's only tobacco crop, and was found by Englishmen to be too bitter for enjoyment. Rolfe, by successfully planting, maintaining, and curing Nicotiana tabacum until sale (by removing all superfluous leaves and applying as little water as possible during curing), made Virginia a potential competitor with Spain's colonies. This transitioned the colony to a cash-crop focused one, monocropping tobacco by 1613, the year the first shipment (of 4 barrels) arrived in London. By 1617, the quality of Virginia tobacco had made it the gold standard in European markets, which have become insatiable- 20,000lbs of tobacco was exported there that year. These exports grew exponentially, doubling to 40,000lbs the following year (the year the first enslaved Africans arrive in America), and reaching 60,000lbs by 1620. The money obtained from tobacco exports was used, in turn, to fund the purchasing of more European indentured servants and especially enslaved Africans to fulfill the rising labor demand. In the 17th century, 75% of all colonists in Virginia had come as servants, indentured (with a term of 4 to 7 years of service) or Africans in perpetuity (for life), the latter being preferred as they were cheaper sources of labor:
== History == Vinblastine was first isolated by Robert Noble and Charles Thomas Beer at the University of Western Ontario from the Madagascar periwinkle plant. The structure of Vinblastine and Vincristine are very similar. There are some differences in their pharmacological effects only and there is no cross-resistance. Vinblastine's utility as a chemotherapeutic agent was first suggested by its effect on the body when an extract of the plant was injected in rabbits to study the plant's supposed anti-diabetic effect. (A tea made from the plant was a folk-remedy for diabetes.) The rabbits died from a bacterial infection, due to a decreased number of white blood cells, so it was hypothesized that vinblastine might be effective against cancers of the white blood cells such as lymphoma. It was approved by FDA in 1965.
The laurel is an evergreen shrub or small tree, variable in size and sometimes reaching 7–18 m (23–59 ft) tall. The genus Laurus includes three accepted species, whose diagnostic key characters often overlap. The bay laurel is dioecious (unisexual), with male and female flowers on separate plants. Each flower is pale yellow-green, about 1 cm (3⁄8 in) diameter, and they are borne in pairs beside a leaf. The leaves are glabrous, 6–12 cm (2–5 in) long and 2–4 cm (3⁄4–1+5⁄8 in) broad, with an entire (untoothed) margin. On some leaves the margin undulates. The fruit is a small, shiny black drupe-like berry about 1 cm (3⁄8 in) long that contains one seed.
=== 1925: White Castle Official House Organ, success, expansion and imitators === The company also began publishing its own internal employee magazine, the White Castle Official House Organ, circa November 1925 (it was originally named The Hot Hamburger). The bulk of the material was contributed by company personnel and consisted mostly of letters and photographs of workers, promotional announcements, 25-year milestones, retirements, and similar items of interest arranged by geographic area. "Employees could... read about the progress and innovations made by those in other areas which made everyone aware of the entire system's direction and condition." The White Castle Official House Organ was published quarterly at least through the early 1980s, and at some point was renamed The Slider Times. The Ohio History Connection houses an extensive archive of White Castle System, Inc. records from 1921 to 1991, including issues dating from 1927 to 1970 of the White Castle Official House Organ.
Roberts with a £300 MRC grant in July 1935, and for the next two years Roberts worked with Florey and Maegraith on Florey's lysozyme project. Still, Florey wanted a biochemist on his own staff. He tried to get Hugh Macdonald Sinclair, but Sinclair declined the offer. Norman Pirie asked Florey if he could assume the role, but when Florey approached Sir Frederick Gowland Hopkins, Pirie's boss, Hopkins refused to release Pirie. He tempered this refusal by recommending Ernst Boris Chain, one of many Jewish refugees from Nazi Germany who had found sanctuary in the UK. Chain had recently completed his PhD thesis under Hopkins's supervision. He gratefully accepted Florey's offer of an appointment although it was initially for one year only, and with an annual salary of £200 (equivalent to £12,000 in 2025). In turn, Chain felt that he needed a collaborator, and he had one in mind: Norman Heatley, who was finishing his PhD in Hopkins's department. Heatley was happy to come, and Florey was able to arrange for the MRC to fund the position.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.